[{"company":"InDex Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"InDex Pharmaceuticals\\' In-depth Analysis of the CONDUCT Study Confirms the Successful Top Line Results","therapeuticArea":"Gastroenterology","highestDevelopmentStatus":"Phase II","country":"SWEDEN","productType":"Large molecule","productStatus":"New Molecular Entity","date":"February 2020","url1":"","url2":"","graph1":"Large molecule","graph2":"InDex Pharmaceuticals"},{"company":"InDex Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"InDex Pharmaceuticals Publishes Mechanism of Action Data for Cobitolimod in Scientific Journal","therapeuticArea":"Gastroenterology","highestDevelopmentStatus":"Phase II","country":"SWEDEN","productType":"Large molecule","productStatus":"New Molecular Entity","date":"February 2020","url1":"","url2":"","graph1":"Large molecule","graph2":"InDex Pharmaceuticals"},{"company":"Cinclus Pharma","sponsor":"Fourth Swedish National Pension Fund","pharmaFlowCategory":"D","amount":"$25.6 million","upfrontCash":"Undisclosed","newsHeadline":"Cinclus Pharma Raises SEK 250 Million for the Continued Development of a Novel Treatment Against Gastroesophageal Reflux Disease","therapeuticArea":"Gastroenterology","highestDevelopmentStatus":"Phase II","country":"SWEDEN","productType":"Small molecule","productStatus":"New Molecular Entity","date":"March 2020","url1":"","url2":"","graph1":"Small molecule","graph2":"Cinclus Pharma"},{"company":"InDex Pharmaceuticals","sponsor":"Vinnova","pharmaFlowCategory":"D","amount":"$0.1 million","upfrontCash":"Undisclosed","newsHeadline":"InDex Pharmaceuticals Receives Grant From Vinnova for Pre-clinical Development of DIMS Compounds in Inflammation","therapeuticArea":"Gastroenterology","highestDevelopmentStatus":"Phase II","country":"SWEDEN","productType":"Large molecule","productStatus":"New Molecular Entity","date":"March 2020","url1":"","url2":"","graph1":"Large molecule","graph2":"InDex Pharmaceuticals"},{"company":"InDex Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"InDex Pharmaceuticals Advances Cobitolimod Further Towards Phase III Following Successful Interactions With FDA and EMA","therapeuticArea":"Gastroenterology","highestDevelopmentStatus":"Phase II","country":"SWEDEN","productType":"Large molecule","productStatus":"New Molecular Entity","date":"April 2020","url1":"","url2":"","graph1":"Large molecule","graph2":"InDex Pharmaceuticals"},{"company":"InDex Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"InDex Pharmaceuticals Presentst Positive Results of the Conduct Study at Two Leading Medical Conferences","therapeuticArea":"Gastroenterology","highestDevelopmentStatus":"Phase II","country":"SWEDEN","productType":"Large molecule","productStatus":"New Molecular Entity","date":"August 2020","url1":"","url2":"","graph1":"Large molecule","graph2":"InDex Pharmaceuticals"},{"company":"InDex Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"The Lancet Gastroenterology and Hepatology publishes InDex Pharmaceuticals\u2019 results of the phase IIb study with cobitolimod","therapeuticArea":"Gastroenterology","highestDevelopmentStatus":"Phase II","country":"SWEDEN","productType":"Large molecule","productStatus":"New Molecular Entity","date":"October 2020","url1":"","url2":"","graph1":"Large molecule","graph2":"InDex Pharmaceuticals"},{"company":"Infant Bacterial Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Infant Bacterial Therapeutics AB (publ) Interim Management Statement, January 1 \u2013 December 31, 2020","therapeuticArea":"Gastroenterology","highestDevelopmentStatus":"Phase II","country":"SWEDEN","productType":"Large molecule","productStatus":"New Molecular Entity","date":"February 2021","url1":"","url2":"","graph1":"Large molecule","graph2":"Infant Bacterial Therapeutics"},{"company":"Infant Bacterial Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Infant Bacterial Therapeutics Expands The Connection Study to Include Infants with a Birth Weight Below 750 Grams","therapeuticArea":"Gastroenterology","highestDevelopmentStatus":"Phase II","country":"SWEDEN","productType":"Large molecule","productStatus":"New Molecular Entity","date":"April 2021","url1":"","url2":"","graph1":"Large molecule","graph2":"Infant Bacterial Therapeutics"},{"company":"InDex Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"InDex Pharmaceuticals Gets Patent for Additional Dims Compounds Granted in Europe","therapeuticArea":"Gastroenterology","highestDevelopmentStatus":"Phase II","country":"SWEDEN","productType":"Large molecule","productStatus":"New Molecular Entity","date":"April 2021","url1":"","url2":"","graph1":"Large molecule","graph2":"InDex Pharmaceuticals"},{"company":"InDex Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"InDex Pharmaceuticals Receives First Regulatory Approval to Start the Phase III Study CONCLUDE With Cobitolimod","therapeuticArea":"Gastroenterology","highestDevelopmentStatus":"Phase II","country":"SWEDEN","productType":"Large molecule","productStatus":"New Molecular Entity","date":"July 2021","url1":"","url2":"","graph1":"Large molecule","graph2":"InDex Pharmaceuticals"},{"company":"Infant Bacterial Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"The Connection Study Continues After Pre-scheduled Data Monitoring Committee (DMC) Review","therapeuticArea":"Gastroenterology","highestDevelopmentStatus":"Phase II","country":"SWEDEN","productType":"Large molecule","productStatus":"New Molecular Entity","date":"January 2022","url1":"","url2":"","graph1":"Large molecule","graph2":"Infant Bacterial Therapeutics"}]
Details:
IBP-9414 (lactobacillus Reuteri), strain-specific attributes which affect the NEC pathogenesis is world’s first approved probiotic drug with the goal to prevent life-threatening diseases in premature infants.
Lead Product(s):
Lactobacillus Reuteri
Therapeutic Area: Gastroenterology
Product Name: IBP-9414
Highest Development Status: Phase II
Product Type: Large molecule
Partner/Sponsor/Collaborator:
Not Applicable
Deal Size: Not Applicable
Upfront Cash: Not Applicable
Deal Type: Not Applicable
January 19, 2022
Details:
The study will evaluate the efficacy and safety of the first-in-class TLR9 agonist cobitolimod for the treatment of moderate to severe left-sided ulcerative colitis.
Lead Product(s):
Cobitolimod
Therapeutic Area: Gastroenterology
Product Name: Kappaproct
Highest Development Status: Phase II
Product Type: Large molecule
Partner/Sponsor/Collaborator:
Not Applicable
Deal Size: Not Applicable
Upfront Cash: Not Applicable
Deal Type: Not Applicable
July 21, 2021
Details:
IBT is developing the drug candidate IBP-9414, contains the active substance Lactobacillus reuteri, which is a human bacterial strain naturally present in breast milk, for the prevention of necrotizing enterocolitis and improvement of feeding tolerance in premature infants.
Lead Product(s):
Lactobacillus Reuteri
Therapeutic Area: Gastroenterology
Product Name: IBP-9414
Highest Development Status: Phase II
Product Type: Large molecule
Partner/Sponsor/Collaborator:
Not Applicable
Deal Size: Not Applicable
Upfront Cash: Not Applicable
Deal Type: Not Applicable
April 29, 2021
Details:
InDex’s Kappaproct is a synthetic oligonucleotides that function as immunomodulatory agents by targeting Toll-like receptor 9 (TLR9). DIMS mimic bacterial DNA, without being harmful, and stimulate immune cells to produce beneficial cytokines.
Lead Product(s):
Cobitolimod
Therapeutic Area: Gastroenterology
Product Name: Kappaproct
Highest Development Status: Phase II
Product Type: Large molecule
Partner/Sponsor/Collaborator:
Not Applicable
Deal Size: Not Applicable
Upfront Cash: Not Applicable
Deal Type: Not Applicable
April 07, 2021
Details:
IBT is currently developing IBP-9414 to prevent necrotizing enterocolitis, and to improve feeding tolerance in premature infants. IBP-9414 contains Lactobacillus reuteri as an active ingredient, which is a human bacterial strain found naturally in breast milk.
Lead Product(s):
Lactobacillus Reuteri
Therapeutic Area: Gastroenterology
Product Name: IBP-9414
Highest Development Status: Phase II
Product Type: Large molecule
Partner/Sponsor/Collaborator:
Not Applicable
Deal Size: Not Applicable
Upfront Cash: Not Applicable
Deal Type: Not Applicable
February 05, 2021
Details:
The study met the primary endpoint and cobitolimod demonstrated an outstanding combination of efficacy and safety.
Lead Product(s):
Cobitolimod
Therapeutic Area: Gastroenterology
Product Name: Kappaproct
Highest Development Status: Phase II
Product Type: Large molecule
Partner/Sponsor/Collaborator:
Not Applicable
Deal Size: Not Applicable
Upfront Cash: Not Applicable
Deal Type: Not Applicable
October 06, 2020
Details:
The CONDUCT study met the primary endpoint with 21.4% of patients in clinical remission at week 6 in the highest dose group receiving 250 mg x 2 cobitolimod, compared with 6.8% of patients in the placebo group.
Lead Product(s):
Cobitolimod
Therapeutic Area: Gastroenterology
Product Name: Kappaproct
Highest Development Status: Phase II
Product Type: Large molecule
Partner/Sponsor/Collaborator:
Not Applicable
Deal Size: Not Applicable
Upfront Cash: Not Applicable
Deal Type: Not Applicable
August 24, 2020
Details:
Company has received positive responses from FDA and EMA regarding phase III development of the company's TLR9 agonist cobitolimod, for the treatment of moderate to severe ulcerative colitis.
Lead Product(s):
Cobitolimod
Therapeutic Area: Gastroenterology
Product Name: Undisclosed
Highest Development Status: Phase II
Product Type: Large molecule
Partner/Sponsor/Collaborator:
Not Applicable
Deal Size: Not Applicable
Upfront Cash: Not Applicable
Deal Type: Not Applicable
April 16, 2020
Details:
The grant will be used for a preclinical project to evaluate selected compounds from InDex's DIMS platform in inflammatory disease models outside the field of inflammatory bowel disease.
Lead Product(s):
Cobitolimod
Therapeutic Area: Gastroenterology
Product Name: Undisclosed
Highest Development Status: Phase II
Product Type: Large molecule
Partner/Sponsor/Collaborator:
Vinnova
Deal Size: $0.1 million
Upfront Cash: Undisclosed
Deal Type: Funding
March 31, 2020
Details:
The proceeds from the financing round will be used to perform a phase 2 clinical trial, which is expected to start in the second half of 2020.
Lead Product(s):
Linaprazan
Therapeutic Area: Gastroenterology
Product Name: Undisclosed
Highest Development Status: Phase II
Product Type: Small molecule
Partner/Sponsor/Collaborator:
Fourth Swedish National Pension Fund
Deal Size: $25.6 million
Upfront Cash: Undisclosed
Deal Type: Financing
March 04, 2020
Market Place
News Type
Upload your Marketing & Sales content on your company Virtual Booth, click HERE
